Literature DB >> 19545642

Epoxyeicosanoid signaling in CNS function and disease.

Jeffrey J Iliff1, Jia Jia, Jonathan Nelson, Toru Goyagi, Judy Klaus, Nabil J Alkayed.   

Abstract

Epoxyeicosatrienoic acids (EETs) are arachidonic acid metabolites of cytochrome P450 epoxygenase enzymes recognized as key players in vascular function and disease, primarily attributed to their potent vasodilator, anti-inflammatory and pro-angiogenic effects. Although EETs' actions in the central nervous system (CNS) appear to parallel those in peripheral tissue, accumulating evidence suggests that epoxyeicosanoid signaling plays different roles in neural tissue compared to peripheral tissue; roles that reflect distinct CNS functions, cellular makeup and intercellular relationships. This is exhibited at many levels including the expression of EETs-synthetic and -metabolic enzymes in central neurons and glial cells, EETs' role in neuro-glio-vascular coupling during cortical functional activation, the capacity for interaction between epoxyeicosanoid and neuroactive endocannabinoid signaling pathways, and the regulation of neurohormone and neuropeptide release by endogenous EETs. The ability of several CNS cell types to produce and respond to EETs suggests that epoxyeicosanoid signaling is a key integrator of cell-cell communication in the CNS, coordinating cellular responses across different cell types. Under pathophysiological conditions, such as cerebral ischemia, EETs protect neurons, astroglia and vascular endothelium, thus preserving the integrity of cellular networks unique to and essential for proper CNS function. Recognition of EETs' intimate involvement in CNS function in addition to their multi-cellular protective profile has inspired the development of therapeutic strategies against CNS diseases such as cerebral ischemia, tumors, and neural pain and inflammation that are based on targeting the cellular actions of EETs or their biosynthetic and metabolizing enzymes. Based upon the emerging importance of epoxyeicosanoids in cellular function and disease unique to neural systems, we propose that the actions of "neuroactive EETs" are best considered separately, and not in aggregate with all other peripheral EETs functions. Copyright 2009 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19545642      PMCID: PMC2844927          DOI: 10.1016/j.prostaglandins.2009.06.004

Source DB:  PubMed          Journal:  Prostaglandins Other Lipid Mediat        ISSN: 1098-8823            Impact factor:   3.072


  147 in total

1.  Tone-dependent vascular responses to astrocyte-derived signals.

Authors:  Víctor M Blanco; Javier E Stern; Jessica A Filosa
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-05-02       Impact factor: 4.733

2.  11,12-Epoxyeicosatrienoic acid stimulates endogenous mono-ADP-ribosylation in bovine coronary arterial smooth muscle.

Authors:  P L Li; C L Chen; R Bortell; W B Campbell
Journal:  Circ Res       Date:  1999-08-20       Impact factor: 17.367

3.  Molecular characterization of an arachidonic acid epoxygenase in rat brain astrocytes.

Authors:  N J Alkayed; J Narayanan; D Gebremedhin; M Medhora; R J Roman; D R Harder
Journal:  Stroke       Date:  1996-05       Impact factor: 7.914

4.  Modulation of the Ca2 permeable cation channel TRPV4 by cytochrome P450 epoxygenases in vascular endothelium.

Authors:  J Vriens; G Owsianik; B Fisslthaler; M Suzuki; A Janssens; T Voets; C Morisseau; B D Hammock; I Fleming; R Busse; B Nilius
Journal:  Circ Res       Date:  2005-09-22       Impact factor: 17.367

5.  A cytochrome P450-derived epoxygenated metabolite of anandamide is a potent cannabinoid receptor 2-selective agonist.

Authors:  Natasha T Snider; James A Nast; Laura A Tesmer; Paul F Hollenberg
Journal:  Mol Pharmacol       Date:  2009-01-26       Impact factor: 4.436

6.  Soluble epoxide hydrolase variant (Glu287Arg) modifies plasma total cholesterol and triglyceride phenotype in familial hypercholesterolemia: intrafamilial association study in an eight-generation hyperlipidemic kindred.

Authors:  Keiko Sato; Mitsuru Emi; Yoichi Ezura; Yuko Fujita; Daisuke Takada; Tomoaki Ishigami; Satoshi Umemura; Yunpei Xin; Lily L Wu; Stacey Larrinaga-Shum; Susan H Stephenson; Steven C Hunt; Paul N Hopkins
Journal:  J Hum Genet       Date:  2003-12-13       Impact factor: 3.172

7.  Epoxyeicosatrienoic acid metabolism in arterial smooth muscle cells.

Authors:  X Fang; M VanRollins; T L Kaduce; A A Spector
Journal:  J Lipid Res       Date:  1995-06       Impact factor: 5.922

8.  Action of luteinizing hormone-releasing hormone: involvement of novel arachidonic acid metabolites.

Authors:  G D Snyder; J Capdevila; N Chacos; S Manna; J R Falck
Journal:  Proc Natl Acad Sci U S A       Date:  1983-06       Impact factor: 11.205

9.  The CYP2J2 G-50T polymorphism and myocardial infarction in patients with cardiovascular risk profile.

Authors:  Jan Börgel; Daniel Bulut; Christoph Hanefeld; Horst Neubauer; Andreas Mügge; Jörg T Epplen; Tim Holland-Letz; Martin Spiecker
Journal:  BMC Cardiovasc Disord       Date:  2008-12-23       Impact factor: 2.298

Review 10.  Genetic variation in the cytochrome P450 epoxygenase pathway and cardiovascular disease risk.

Authors:  Katherine N Theken; Craig R Lee
Journal:  Pharmacogenomics       Date:  2007-10       Impact factor: 2.533

View more
  62 in total

1.  Soluble epoxide hydrolase as an anti-inflammatory target of the thrombolytic stroke drug SMTP-7.

Authors:  Naoki Matsumoto; Eriko Suzuki; Makoto Ishikawa; Takumi Shirafuji; Keiji Hasumi
Journal:  J Biol Chem       Date:  2014-10-31       Impact factor: 5.157

Review 2.  The physiology of developmental changes in BOLD functional imaging signals.

Authors:  Julia J Harris; Clare Reynell; David Attwell
Journal:  Dev Cogn Neurosci       Date:  2011-04-27       Impact factor: 6.464

3.  Soluble epoxide hydrolase: sex differences and role in endothelial cell survival.

Authors:  Nandita C Gupta; Catherine M Davis; Jonathan W Nelson; Jennifer M Young; Nabil J Alkayed
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-06-21       Impact factor: 8.311

4.  Soluble epoxide hydrolase inhibition provides multi-target therapeutic effects in rats after spinal cord injury.

Authors:  Xiaojing Chen; Xiaoqi Chen; Xiaojiang Huang; Chuan Qin; Yongkang Fang; Yang Liu; Guibing Zhang; Dengji Pan; Wei Wang; Minjie Xie
Journal:  Mol Neurobiol       Date:  2015-02-10       Impact factor: 5.590

Review 5.  Cytochrome P450 eicosanoids and cerebral vascular function.

Authors:  John D Imig; Alexis N Simpkins; Marija Renic; David R Harder
Journal:  Expert Rev Mol Med       Date:  2011-03-01       Impact factor: 5.600

Review 6.  Sex differences in stroke: the contribution of coagulation.

Authors:  Meaghan Roy-O'Reilly; Louise D McCullough
Journal:  Exp Neurol       Date:  2014-02-19       Impact factor: 5.330

Review 7.  Modulation of innate immunity of patients with Alzheimer's disease by omega-3 fatty acids.

Authors:  Milan Fiala; Gijs Kooij; Karen Wagner; Bruce Hammock; Matteo Pellegrini
Journal:  FASEB J       Date:  2017-04-18       Impact factor: 5.191

8.  5,6-EET potently inhibits T-type calcium channels: implication in the regulation of the vascular tone.

Authors:  Magali Cazade; Isabelle Bidaud; Pernille B Hansen; Philippe Lory; Jean Chemin
Journal:  Pflugers Arch       Date:  2013-12-11       Impact factor: 3.657

Review 9.  Cytochrome P450 epoxygenase pathway of polyunsaturated fatty acid metabolism.

Authors:  Arthur A Spector; Hee-Yong Kim
Journal:  Biochim Biophys Acta       Date:  2014-08-02

10.  Soluble epoxide hydrolase inhibitor trans-4-[4-(3-adamantan-1-yl-ureido)-cyclohexyloxy]-benzoic acid is neuroprotective in rat model of ischemic stroke.

Authors:  Jafar Sadik B Shaik; Muzamil Ahmad; Wenjin Li; Marie E Rose; Lesley M Foley; T Kevin Hitchens; Steven H Graham; Sung Hee Hwang; Bruce D Hammock; Samuel M Poloyac
Journal:  Am J Physiol Heart Circ Physiol       Date:  2013-09-16       Impact factor: 4.733

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.